Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Prostatic Neoplasms 19Prostatic Neoplasms, Castration-Resistant 5Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Metastatic Castrate-Resistant Prostate Cancer 2Melanoma 2Endometrial Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2mCRPC 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Metastatic Castration-Resistant Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer 1Mesothelioma, Malignant 1Lymphoproliferative Disorders 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

pembrolizumab 30Nivolumab 15Paclitaxel 13Cyclophosphamide 12Carboplatin 12sacituzumab govitecan 8Cisplatin 8Capecitabine 7130-nm albumin-bound paclitaxel 7Gemcitabine 6fludarabine 5durvalumab 5avelumab 5atezolizumab 5Magnetic Resonance Spectroscopy 5Ipilimumab 5Biopsy 5camrelizumab 4Specimen Handling 4Interleukin-2 4Injections 4Immune Checkpoint Inhibitors 4Docetaxel 4toripalimab 3talazoparib 3Leucovorin 3Everolimus 3Clinical Trials, Phase II as Topic 3Bevacizumab 3yeast-CEA vaccine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Triple Negative Breast Neoplasms × enzalutamide × Clear all
NCT05057013 2025-08-11

A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

Cancer Research UK

Phase 1/2 Active not recruiting
81 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Lethal Congenital Contracture Syndrome 2, Fibromatosis, Gingival, 2, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Prostatic Neoplasms, Castration-Resistant, Triple Negative Breast Neoplasms

NCT02457910 2022-08-22

Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

Vanderbilt-Ingram Cancer Center

Phase 1/2 Terminated
30 enrolled 14 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡